ZOSTAVAX Powder and solvent for suspension for injection Ref.[9861] Active ingredients: Attenuated varicella-zoster virus

Source: European Medicines Agency (EU)  Revision Year: 2022  Publisher: Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands

Product name and form

ZOSTAVAX powder and solvent for suspension for injection.
ZOSTAVAX powder and solvent for suspension for injection in a pre-filled syringe.

shingles (herpes zoster) vaccine (live)

Pharmaceutical Form

Powder and solvent for suspension for injection.

The powder is a white to off-white compact crystalline plug.
The solvent is a clear, colourless fluid.

Qualitative and quantitative composition

After reconstitution, 1 dose (0.65 mL) contains: Varicella-zoster virus1, Oka/Merck strain, (live, attenuated) not less than 19,400 PFU2.

1 produced in human diploid (MRC-5) cells
2 PFU = Plaque-forming units

This vaccine may contain traces of neomycin. See sections 4.3 and 4.4.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Attenuated varicella-zoster virus

Varicella-zoster virus vaccine was shown to boost VZV-specific immunity, which is thought to be the mechanism by which it protects against zoster and its complications.

List of Excipients

Powder:

Sucrose
Hydrolysed gelatin
Sodium chloride
Potassium dihydrogen phosphate
Potassium chloride
Monosodium L-glutamate monohydrate
Disodium phosphate
Sodium hydroxide (to adjust pH)
Urea

Solvent:

Water for injections

Pack sizes and marketing

ZOSTAVAX with solvent for reconstitution supplied in a vial: Powder in a vial (glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a vial (glass) with a stopper (chlorobutyl rubber) and flip off cap (aluminium) in a pack size of 1 or 10.

ZOSTAVAX with solvent for reconstitution supplied in a pre-filled syringe: Powder in a vial (glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a pre-filled syringe (glass) with plunger stopper (chlorobutyl rubber) and tip cap (styrene-butadiene rubber) with one or two unattached needles in a pack size of 1, 10 or 20.

Powder in a vial (glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a pre-filled syringe (glass) with plunger stopper (chlorobutyl rubber) and tip cap (styrene-butadiene rubber) without needle in pack size of 1, 10 or 20.

Not all pack sizes may be marketed.

Marketing authorization holder

Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands

Marketing authorization dates and numbers

EU/1/06/341/001
EU/1/06/341/002
EU/1/06/341/005
EU/1/06/341/006
EU/1/06/341/007
EU/1/06/341/008
EU/1/06/341/009
EU/1/06/341/010
EU/1/06/341/011
EU/1/06/341/012
EU/1/06/341/013

Date of first authorisation: 19 May 2006
Date of latest renewal: 11 February 2016

Drugs

Drug Countries
ZOSTAVAX Austria, Brazil, Canada, Cyprus, Estonia, Spain, France, Hong Kong, Ireland, Israel, Lithuania, Netherlands, New Zealand, Poland, Singapore, United Kingdom, United States, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.